ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2020
The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
China Cognition and Aging Study: a Multi-center, National-wide, Longitudinal Study in China
A Multi-center Longitudinal Cohort Study of Familial Alzheimer's Disease in China
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Protective effect of apolipoprotein E epsilon 3 on sporadic Alzheimer's disease in the Chinese population: a meta-analysis.Scientific reports · 2022Pooled it
- Angiotensin-converting enzyme polymorphisms AND Alzheimer's disease susceptibility: An updated meta-analysis.PloS one · 2021Pooled it
- Accelerated hippocampal atrophy in APOE ε4 homozygotes and females: Longitudinal findings from the Tohoku Medical Megabank MRI study.Neuroradiology · 2026Article
- Examining APOE ε4 and Longitudinal Vascular Brain Injury: The Strong Heart Study.Neurology open access · 2026Article
- Apolipoprotein E e4 Status Predicts Memory Performance and Daily Functioning in Aging Hispanic/Latino Adults.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- Deviations from additivity in APOE4-mediated late-onset Alzheimer's disease risk across races and ethnicities.Human genetics · 2026Article
- Hippocampal subregional texture features associated with Alzheimer's disease severity and cognition.Brain communications · 2026Article
- The hypoperfusion intensity ratio associates with APOE gene polymorphism in acute ischemic stroke patients with large vessel occlusion.Scientific reports · 2025Article
- Review
- Uncovering dark mass in population proteomics: Pan-analysis of single amino acid polymorphism relevant to cognition and aging.Cell genomics · 2025Article
- Global, regional, and national burden of Alzheimer's disease and other dementias from 1990 to 2021: findings from the Global Burden of Disease Study 2021.Frontiers in aging neuroscience · 2025Article
- Article
- Precision Medicine in Neurodegenerative Diseases: Genomic Approaches to Target Amyloid-β, Tau, and Alpha-Synuclein Pathways.Current genomics · 2025Review
- Pharmacogenetics or predictive genetics? APOE testing blurs the lines.Frontiers in pharmacology · 2025Review
- Bibliometric analysis of neural injury biomarkers in neurodegenerative diseases: research trends and future perspectives.Frontiers in human neuroscience · 2025Article
- Exosomal MicroRNAs in Alzheimer's Disease: Unveiling Their Role and Pioneering Tools for Diagnosis and Treatment.Journal of clinical medicine · 2024Review
- The roles of apolipoprotein E ε4 on neuropathology and neuroinflammation in patients with Alzheimer's disease.CNS neuroscience & therapeutics · 2024Article
- sPDGFRβ and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Research Progress of Mitophagy in Alzheimer's Disease.Current Alzheimer research · 2024Review
- How Modifiable Are Modifiable Dementia Risk Factors? A Framework for Considering the Modifiability of Dementia Risk Factors.The journal of prevention of Alzheimer's disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe genetic risk effects of apolipoprotein E (APOE) on familial Alzheimer's disease (FAD) with or without gene mutations, sporadic AD (SAD), and normal controls (NC) remain unclear in the Chinese population.
methodsIn total, 15 119 subjects, including 311 FAD patients without PSEN1, PSEN2, APP, TREM2, and SORL1 pathogenic mutations (FAD [unknown]); 126 FAD patients with PSENs/APP mutations (FAD [PSENs/APP]); 7234 SAD patients; and 7448 NC were enrolled. The risk effects of APOE ε4 were analyzed across groups.
resultsThe prevalence of the APOE ε4 genotype in FAD (unknown), FAD (PSENs/APP), SAD, and NC groups was 56.27%, 26.19%, 36.23%, and 19.54%, respectively. Further, the APOE ε4 positive genotype had predictive power for FAD (unknown) risk (odds ratio: 4.51, 95% confidence interval: 3.57-5.45, P < .001). DISCUSSION: APOE ε4 positive genotype may cause familial aggregation, and the investigation of multiple interventions targeting APOE pathological function to reduce the risk for this disease warrants attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.